Last reviewed · How we verify
Moderately severe to severe infections of the upper-respiratory tract
Approved treatments
- Bicillin C-R · Pfizer Inc.
Penicillin G inhibits bacterial cell-wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderately severe to severe infections of the upper-respiratory tract patent landscape — cliff calendar, originator estates, attackable patents
- Moderately severe to severe infections of the upper-respiratory tract treatment landscape brief
- Moderately severe to severe infections of the upper-respiratory tract treatment updates RSS
Frequently asked questions about Moderately severe to severe infections of the upper-respiratory tract
What drugs treat Moderately severe to severe infections of the upper-respiratory tract?
Tracked treatments include Bicillin C-R.
What is the treatment for Moderately severe to severe infections of the upper-respiratory tract?
Standard treatment for Moderately severe to severe infections of the upper-respiratory tract includes Bicillin C-R. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderately severe to severe infections of the upper-respiratory tract patent cliff · Moderately severe to severe infections of the upper-respiratory tract CI report
- Treatment: Bicillin C-R · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing